Canadian regulators wade into Alzheimer’s drug controversy
In June 2022, neuroscience firm Biogen withdrew its Canadian drug submission for approval of aducanumab, which is a monoclonal antibody drug for the treatment of Alzheimer’s disease (AD). The company’s statement...To view the full article, register now.
Already a subscriber? Click here to view full article